Arcus Biosciences (RCUS) Research & Development (2017 - 2026)
Arcus Biosciences (RCUS) posted quarterly Research & Development of $122.0 million for Q1 2026, little changed year-over-year from $122.0 million in Q1 2025, and up 0.83% quarter-over-quarter from $121.0 million in Q4 2025.
Arcus Biosciences (RCUS) Research & Development (2017 - 2026) Analysis & Trends
Arcus Biosciences' Research & Development history runs 10 years deep, the most recent figure standing at $122.0 million for Q1 2026.
- In Q1 2026, Research & Development changed 0.0% year-over-year to $122.0 million; the TTM figure through Mar 2026 stood at $523.0 million (up 13.45% YoY), while the FY2025 annual figure was $523.0 million, up 16.74% from the prior year.
- Research & Development for Q1 2026 stood at $122.0 million, up from $121.0 million in the prior quarter.
- The five-year high for Research & Development was $141.0 million in Q3 2025, with the low at $61.0 million in Q1 2022.
- The 5-year median for Research & Development is $101.0 million (2024), against an average of $101.2 million.
- Peak annual rise in Research & Development reached 58.14% in 2022, while the deepest fall reached 8.11% in 2022.
- Arcus Biosciences' Research & Development stood at $80.0 million in 2022, then advanced by 16.25% to $93.0 million in 2023, then gained by 8.6% to $101.0 million in 2024, then advanced by 19.8% to $121.0 million in 2025, then advanced by 0.83% to $122.0 million in 2026.
- Business Quant data shows RCUS's Research & Development at $122.0 million in Q1 2026, $121.0 million in Q4 2025, and $141.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Arcus Biosciences | 3.74 Bn | 3.04 Bn | - | 113.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 113.00 Mn |
| Mar 31, 2026 | 122.00 Mn |
| Dec 31, 2025 | 121.00 Mn |
| Sep 30, 2025 | 141.00 Mn |
| Jun 30, 2025 | 139.00 Mn |
| Mar 31, 2025 | 122.00 Mn |
| Dec 31, 2024 | 101.00 Mn |
| Sep 30, 2024 | 123.00 Mn |
| Jun 30, 2024 | 115.00 Mn |
| Mar 31, 2024 | 109.00 Mn |
| Dec 31, 2023 | 93.00 Mn |
| Sep 30, 2023 | 82.00 Mn |
| Jun 30, 2023 | 84.00 Mn |
| Mar 31, 2023 | 81.00 Mn |
| Dec 31, 2022 | 80.00 Mn |
| Sep 30, 2022 | 77.00 Mn |
| Jun 30, 2022 | 70.00 Mn |
| Mar 31, 2022 | 61.00 Mn |
| Dec 31, 2021 | 50.59 Mn |
| Sep 30, 2021 | 71.25 Mn |